Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

TRYPTOPHAN

All products: not a benefit

Ratio-Tryptophan · DIN 02237250 · 1g · tablet

Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2025-01-28 — choose a marketed DIN from the same-category list.Discontinued 2025-01-28 · checked 2026-09-20
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2025-01-28 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2025-01-28 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Ratio-Tryptophan · DIN 02237250 Manufacturer: Ratiopharm Inc.; listing date 2000-04-17 Health Canada: Cancelled post market since 2025-01-28 · brand TEVA-TRYPTOPHAN · ATC N06AX02 TRYPTOPHAN · form Tablet · route Oral · ingredients TRYPTOPHAN 1 G · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=60571 · Verify on the e-Formulary ↗ (DIN 02237250)

Source record
DIN 02237250: Ratio-Tryptophan Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 281612030; group id 513; item number 1360; lccId None; manufacturer id RPH Source form: Tab; strength: 1g Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.8978; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02237250 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=60571
Interchangeable products
Apo-Tryptophan · DIN 02248539 · not recorded Tryptan · DIN 00654531 · not recorded
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since 2025-01-28 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (28:16:12 Other Psychotropics) and how they are covered

Matched class: 28:16:12 Other Psychotropics

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Some products covered without a code (check the product listing): LITHIUM CARBONATE 28:16:12 Other Psychotropics

LITHIUM CARBONATE

· 12 products · General benefit (10), Off-Formulary Interchangeable, not an ODB benefit (2) · strengths: 150mg, 300mg · Cap, ER Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:16:12
Full class listing Related classes: 28:08:04 Nonsteroidal Anti-Inflammatory Agents, 28:08:08 Opiate Agonists, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:04 Antidepressants, 28:16:08 Tranquilizers, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS TRYPTAN is indicated: as a valuable adjunct to antidepressant drug treatment in the management of patients suffering from depressive disorders (bipolar affective disorders). https://pdf.hres.ca/dpd_pm/00061741.PDF PM date: June 9, 2021 Source product: TRYPTAN; DIN 00654531; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Ratio-Tryptophan: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026